

Frequencies

[DataSet7]

Statistics

		basal insulin	prandial insulin	SGLT2i	GLP-1RA	DPP-4i	Combinations
N	Valid	27	27	27	27	27	0
	Missing	0	0	0	0	0	27

Statistics

		patient gender	patient insurance type	metformin use	sulfonylurea use	meglitinide use
N	Valid	27	27	27	27	27
	Missing	0	0	0	0	0

Statistics

		TZD use	other insulin use
N	Valid	27	27
	Missing	0	0

Frequency Table

basal insulin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		13	48.1	48.1	48.1
	Basaglar	8	29.6	29.6	77.8
	Lantus	2	7.4	7.4	85.2
	Levemir	1	3.7	3.7	88.9
	Tresiba	3	11.1	11.1	100.0
	Total	27	100.0	100.0	

prandial insulin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		22	81.5	81.5	81.5
	Humalog	3	11.1	11.1	92.6
	Novolog	2	7.4	7.4	100.0
	Total	27	100.0	100.0	

SGLT2i

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		25	92.6	92.6	92.6
	Farxiga	1	3.7	3.7	96.3
	Jardiance	1	3.7	3.7	100.0
	Total	27	100.0	100.0	

GLP-1RA

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		8	29.6	29.6	29.6
	Ozempic	6	22.2	22.2	51.9
	Trulicity	13	48.1	48.1	100.0
	Total	27	100.0	100.0	

DPP-4i

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		26	96.3	96.3	96.3
	nonPAP DPP4	1	3.7	3.7	100.0
	Total	27	100.0	100.0	

Combinations

		Frequency	Percent
Missing	System	27	100.0

patient gender

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	female	14	51.9	51.9	51.9
	male	13	48.1	48.1	100.0
	Total	27	100.0	100.0	

patient insurance type

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Medicare part D	26	96.3	96.3	96.3
	No insurance	1	3.7	3.7	100.0
	Total	27	100.0	100.0	

metformin use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	10	37.0	37.0	37.0
	Yes - both	16	59.3	59.3	96.3
	Yes-12 months only	1	3.7	3.7	100.0
	Total	27	100.0	100.0	

sulfonylurea use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	18	66.7	66.7	66.7
	Yes both baseline and 12 months	3	11.1	11.1	77.8
	Yes- 12 months only	1	3.7	3.7	81.5
	Yes- baseline only	5	18.5	18.5	100.0
	Total	27	100.0	100.0	

meglitinide use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	27	100.0	100.0	100.0

TZD use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	27	100.0	100.0	100.0

other insulin use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	11	40.7	40.7	40.7
	Yes baseline and 12 months	11	40.7	40.7	81.5
	Yes- baseline only	5	18.5	18.5	100.0
	Total	27	100.0	100.0	

T-Test

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	total # meds prior to PAP	11.26	27	2.890	.556
	total # meds 6 months after PAP	11.52	27	3.005	.578
Pair 2	total # DM meds prior to PAP	2.52	27	.802	.154
	total # DM meds 6 months after PAP	2.41	27	.797	.153
Pair 3	baseline A/C ratio	84.324	21	138.9195	30.3147
	12 month A/C ratio	48.486	21	65.0266	14.1900
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1)	1.59	27	.636	.122
	# renal protective meds 12 months	1.70	27	.669	.129
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1)	2.33	27	.784	.151
	# CV protective meds 12 months	2.44	27	.751	.145
Pair 6	# hypoglycemia potential meds baseline	1.07	27	.829	.159
	# hypoglycemia potential meds 12 months	.93	27	.781	.150

Paired Samples Correlations

		N	Correlation	Significance	
				One-Sided p	Two-Sided p
Pair 1	total # meds prior to PAP & total # meds 6 months after PAP	27	.901	<.001	<.001
Pair 2	total # DM meds prior to PAP & total # DM meds 6 months after PAP	27	.860	<.001	<.001
Pair 3	baseline A/C ratio & 12 month A/C ratio	21	.917	<.001	<.001
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) & # renal protective meds 12 months	27	.700	<.001	<.001
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) & # CV protective meds 12 months	27	.849	<.001	<.001
Pair 6	# hypoglycemia potential meds baseline & # hypoglycemia potential meds 12 months	27	.841	<.001	<.001

Paired Samples Test

		Paired Differences			95% Confidence Interval of the ...
		Mean	Std. Deviation	Std. Error Mean	Lower
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	-.259	1.318	.254	-.781
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	.111	.424	.082	-.056
Pair 3	baseline A/C ratio - 12 month A/C ratio	35.8381	83.3804	18.1951	-2.1162
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	-.111	.506	.097	-.311
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	-.111	.424	.082	-.279

Paired Samples Test

		Paired ... 95% Confidence Interval of the ...	Significance			
		Upper	t	df	One-Sided p	Two-Sided p
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	.262	-1.022	26	.158	.316
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	.279	1.363	26	.092	.185
Pair 3	baseline A/C ratio - 12 month A/C ratio	73.7924	1.970	20	.031	.063
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	.089	-1.140	26	.132	.265
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	.056	-1.363	26	.092	.185

Paired Samples Test

		Paired Differences			95% Confidence Interval of the ...
		Mean	Std. Deviation	Std. Error Mean	Lower
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	.148	.456	.088	-.032

Paired Samples Test

		Paired ... 95% Confidence Interval of the ...	Significance			
		Upper	t	df	One-Sided p	Two-Sided p
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	.329	1.688	26	.052	.103

Paired Samples Effect Sizes

			Standardizer ^a	Point Estimate	95% ... Lower
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	Cohen's d	1.318	-.197	-.576
		Hedges' correction	1.358	-.191	-.559
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	Cohen's d	.424	.262	-.124
		Hedges' correction	.436	.255	-.120
Pair 3	baseline A/C ratio - 12 month A/C ratio	Cohen's d	83.3804	.430	-.023
		Hedges' correction	86.6790	.413	-.022
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	Cohen's d	.506	-.219	-.599
		Hedges' correction	.522	-.213	-.582
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	Cohen's d	.424	-.262	-.644
		Hedges' correction	.436	-.255	-.625
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	Cohen's d	.456	.325	-.065
		Hedges' correction	.470	.315	-.063

Paired Samples Effect Sizes

			95% ... Upper
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	Cohen's d	.186
		Hedges' correction	.181
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	Cohen's d	.644
		Hedges' correction	.625
Pair 3	baseline A/C ratio - 12 month A/C ratio	Cohen's d	.873
		Hedges' correction	.839
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	Cohen's d	.164
		Hedges' correction	.160
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	Cohen's d	.124
		Hedges' correction	.120
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	Cohen's d	.709
		Hedges' correction	.689

- a. The denominator used in estimating the effect sizes.
Cohen's d uses the sample standard deviation of the mean difference.
Hedges' correction uses the sample standard deviation of the mean difference, plus a correction factor.

Bayesian One-way Repeated Measures ANOVA

Case Processing Summary

	N	Percent
Included	21	77.8%
Excluded	6	22.2%
Total	27	100.0%

Descriptive Statistics of Within-Subject Factor Levels

Dependent Variables	Mean	Std. Deviation	N	Min	Max
baseline A1c	8.114	1.9825	21	5.9	13.0
6 month A1c	7.224	1.0592	21	5.4	9.7
12 month A1c	7.214	1.4150	21	5.2	10.7

Bayesian Estimates of Group Means^a

Dependent Variables	Mode	Posterior		95% Credible Interval	
		Mean	Variance	Lower Bound	Upper Bound
baseline A1c	8.114	8.114	.107	7.474	8.754
6 month A1c	7.224	7.224	.107	6.584	7.864
12 month A1c	7.214	7.214	.107	6.574	7.854

a. Posterior distribution was estimated based on the Bayesian Central Limit Theorem.

Bayesian One-way Repeated Measures ANOVA

Case Processing Summary

	N	Percent
Included	23	85.2%
Excluded	4	14.8%
Total	27	100.0%

Descriptive Statistics of Within-Subject Factor Levels

Dependent Variables	Mean	Std. Deviation	N	Min	Max
baseline weight (kg)	98.565	22.0897	23	53.3	143.9
6 month weight	95.987	20.4393	23	56.1	137.8
12 month weight	94.313	20.1143	23	52.8	131.8

Bayesian Estimates of Group Means^a

Dependent Variables	Mode	Posterior		95% Credible Interval	
		Mean	Variance	Lower Bound	Upper Bound
baseline weight (kg)	98.565	98.565	18.164	90.212	106.918
6 month weight	95.987	95.987	18.164	87.634	104.340
12 month weight	94.313	94.313	18.164	85.960	102.666

a. Posterior distribution was estimated based on the Bayesian Central Limit Theorem.

Descriptives

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
# of patient assistance medications	27	1	3	1.48	.700
patient age	27	48	84	69.26	7.654
Valid N (listwise)	27				

